Moul J - Search Results

1

Prostate cancer early detection. Clinical practice guidelines in oncology.

Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet GP 3rd, Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, Nadler RB, Patterson S, Pollack A, Presti JC, Stroup AM, Urban DA, Wake R, Wei JT; National Comprehensive Cancer Network. Kawachi MH, et al. Among authors: moul j. J Natl Compr Canc Netw. 2007 Aug;5(7):714-36. J Natl Compr Canc Netw. 2007. PMID: 17692177 No abstract available.

2

Clinical staging of prostate cancer: reproducibility and clarification of issues.

Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, Montie J, Moul J, Pollack A, Raghavan D, Ray P, Roach M 3rd, Steinberg G, Stone N, Thompson I, Vogelzang N, Vijayakumar S. Campbell T, et al. Among authors: moul j. Int J Cancer. 2001 Jun 20;96(3):198-209. doi: 10.1002/ijc.1017. Int J Cancer. 2001. PMID: 11410889

3

Screening for prostate cancer in high risk populations.

Catalona WJ, Antenor JA, Roehl KA, Moul JW. Catalona WJ, et al. Among authors: moul jw. J Urol. 2002 Nov;168(5):1980-3; discussion 1983-4. doi: 10.1016/S0022-5347(05)64276-0. J Urol. 2002. PMID: 12394689

4

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. D'Amico AV, et al. Among authors: moul j. J Clin Oncol. 2003 Jun 1;21(11):2163-72. doi: 10.1200/JCO.2003.01.075. J Clin Oncol. 2003. PMID: 12775742

5

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. D'Amico AV, et al. J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83. doi: 10.1093/jnci/djg043. J Natl Cancer Inst. 2003. PMID: 13130113

6

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. D'Amico AV, et al. J Natl Cancer Inst. 2004 Apr 7;96(7):509-15. doi: 10.1093/jnci/djh086. J Natl Cancer Inst. 2004. PMID: 15069112

7

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. D'Amico AV, et al. Among authors: moul j. J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7. doi: 10.1097/01.ju.0000141845.99899.12. J Urol. 2004. PMID: 15535442

8

Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. D'Amico AV, et al. Among authors: moul j. J Urol. 2005 May;173(5):1572-6. doi: 10.1097/01.ju.0000157569.59229.72. J Urol. 2005. PMID: 15821488

9

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.

Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Stewart AJ, et al. Among authors: moul jw. J Clin Oncol. 2005 Sep 20;23(27):6556-60. doi: 10.1200/JCO.2005.20.966. J Clin Oncol. 2005. PMID: 16170163

10

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Zhou P, et al. J Clin Oncol. 2005 Oct 1;23(28):6992-8. doi: 10.1200/JCO.2005.01.2906. J Clin Oncol. 2005. PMID: 16192586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

569 results

Search Page

Filters